Fusokines involving cytokines with strongly reduced receptor binding affinities
AssigneesVib Vzw, Universiteit Gent, Centre National De Le Recherche Scientifque, Universite De Montpellier, Centre Hospitalier Regional Universitaire De Montpellier
InventorsJan Tavernier, Jennyfer Bultinck, Sarah Gerlo, Gilles Uze, Franciane Paul, Yann Bordat
Life of this patent
Estimating the term…
Abstract
The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
Claims2
A composition comprising a fusion protein comprising at least two cytokines, wherein the cytokines are single chain tumor necrosis factor alpha (scTNFα) and mutant leptin and wherein leptin comprises a mutation selected from L86S and L86N that reduces binding activity of leptin to its receptor as compared to wild type leptin and scTNFα is wild-type and provides cell-specific targeting that restores activity of the mutant leptin on the targeted cells.
Dependencies are inferred from the claim text.